Shots:
- Biocytogen has entered into an evaluation & option agreement with Merck KGaA to develop antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, incl. antibody-conjugated lipid nanoparticles
- As per the deal, Biocytogen will provide fully human antibodies from its RenMice platform for evaluation to Merck KGaA’s antibody-conjugated LNP services, with Merck KGaA holding an exclusive option to acquire selected assets for fees & royalties on sales & sublicenses
- RenMice antibody discovery platform features RenMab, RenLite, RenNano & RenTCRmimic to discover fully human monoclonal/bispecific/multispecific antibody, bispecific ADC, nanobody & TCR mimic antibody, respectively
Ref: Biocytogen| Image: Biocytogen & Merck KGaA | Press Release
Related News:- Biocytogen Pharmaceuticals Enters a Licensing Agreement with BeOne Medicines for Multiple Antibody Candidates
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
